Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Do you avoid high-potency P2Y12 inhibitors in favor of clopidogrel in patients with atrial fibrillation on a DOAC who undergo PCI?
Tannu M, et al, PMID 39918467
Related Questions
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
Would you defer or opt for plavix loading in a patient already on DAPT presenting with NSTEMI attributed to non-ischemic myocardial injury but with known CAD?
What is your preferred duration for triple therapy post-PCI in patients on systemic anticoagulation?
What is a reasonable timeline for a left heart catheterization in a patient with newly diagnosed severe LV systolic dysfunction of unclear etiology and without an ACS presentation?
What is your preferred P2Y12 inhibitor to use upstream of STEMI cases, if you decide to administer an agent before proceeding to the cath lab?
For patients presenting with suspected type 1 NSTEMI and atrial fibrillation on anticoagulation, do you favor triple therapy or SAPT with systemic anticoagulation instead while awaiting LHC?
Do you always give 325mg aspirin if not already loaded with antiplatelets prior to the start of every LHC, even just for diagnostics in the absence of ACS?
What has been your experience with Coronary CTA with FFR results and its ability to accurately predict epicardial CAD on diagnostic LHC?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
When do you consider revascularizing chronic total occlusions after failing medical management?
